Please login to the form below
Servier
This page shows the latest Servier news and features for those working in and with pharma, biotech and healthcare.
Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer
Alongside Onivyde, which the company is developing with Servier, the Nalirifox regimen contains 5-Fluorouracil, as well as oxaliplatin and leucovorin.
Latest news
-
London High Court rules in favour of NHS in Servier drug dispute
As a counter to this, Servier contended that damages to the NHS should be reduced because the NHS should have taken appropriate steps to avoid buying its more expensive product. ... In response to this, Servier’s own expert witness commented the claims
-
UK Supreme Court rules in favour of Servier in NHS patent lawsuit
The UK Supreme Court has unanimously ruled in favour of French pharma company Servier over a decade-long patent case filed by the NHS regarding the hypertension drug Coversyl. ... Servier obtained a court injunction to prevent generic sales of the drug
-
Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration
All told, Servier could pay up to 320m in milestone payments to Oncodesign, as well as royalties on potential future sales. ... In February 2020, Oncodesign received the first milestone payment as part of the collaboration with Servier, receiving 1m
-
Servier to acquire Agios’ oncology business in $1.8bn deal
We look forward to welcoming the experienced Agios oncology teams to Servier following the closing,” added Laureau. ... Servier will continue to conduct certain clinical development activities within the Idhifa development programme.
-
Galapagos mid-stage trial failure raises concerns for Gilead deal
Galapagos and its development partner for GLPG1972 Servier announced that the drug failed to improve outcomes in the phase 2 ROCCELLA study of knee osteoarthritis patients and was also unable to
More from news
Approximately 29 fully matching, plus 86 partially matching documents found.
Latest Intelligence
-
Health trust in a COVID-19 world – a unique opportunity for pharma
Our team there hypothesised that this may be due to several highly publicised issues including Servier’s long-awaited trial over the safety of a weight loss drug, a large, monthslong
-
20 for 2020 – Five pharma leaders to watch in 2020
Servier has rights to the latter elsewhere. Galapagos gets access to Gilead’s marketing muscle and broader presence in international markets, as well as help as it follows the path towards
-
2019: CRISPR and therapeutic gene editing comes of age
At this year’s American Society of Haematology (ASH) meeting, Allogene and partner Servier presented phase 1 data for their UCART19 candidate in ALL which revealed impressive response rates.
-
Pharma deals continue to slide
The Xoma licensing deal is interesting because it required Novartis to settle the $14m debt owed to Xoma’s previous licensee Servier.
-
Deal Watch March 2017
name. (Abexinostat was formerly in development by Pharmacyclics (now owned by AbbVie) and Servier.) Both ACAT-1 (for which Xynomic paid $1.2m upfront with another $59m in potential milestones) and
More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.
Latest appointments
-
EFPIA confirms first and second vice-presidents
Novo Nordisk CEO Lars Fruergaard Jørgensen appointed first vice-president and Servier president Olivier Laureau confirmed as second vice-president. ... Fruergaard Jørgensen currently serves as the president and chief executive officer of Novo Nordisk,
-
Gerry Crawford to head up Health4Brands
Finally Kyme - whose experience includes stints industry-side with Servier as well as in publishing with the Nature group - aims to broaden the agency's clinical expertise with her experience of
-
Johan Heylen leaves GSK for Ablynx
Heylen also has experience at Servier and Wyeth having started his career in healthcare as a pharmacist.
-
Polyhedra appoints Steve Hobbs chief business development officer
He brings to Polyheda over 30 years international experience in pharmaceuticals and healthcare, gained at firms such as Boehringer Mannheim, Servier Laboratories and Innovex UK, the latter of which saw Hobbs
-
Lundbeck's Steve Turley re-elected as EMG chair
Robin Bhattacherjee as vice-chair, and electing Servier's Mike Sumpter as treasurer. ... Prior to this, he spent 16 years at Bayer. Meanwhile, Mike Sumpter has been CEO of Servier's UK business since 2008, a role that was preceded by a spell as
More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Medscape Medical Affairs Celebrate a Double Win at the PMEAs
The entry describes the collaboration between L’Institut Servier, Gustave Roussy (Villejuif, France), Dana-Farber Cancer Institute (Boston, USA), and Medscape Medical Affairs to establish a global community of innovators across
-
Medscape Medical Affairs are PMEA Finalists in Three Categories
Excellence in Collaboration and Partnerships. The entry describes the collaboration between L’Institut Servier, Gustave Roussy (Villejuif, France), Dana-Farber Cancer Institute (Boston, USA), and Medscape Medical Affairs to establish a
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
